Breaking News

Frontage Gains Schedule I-II Drug Approval from DEA

By Kristin Brooks | December 10, 2013

Expands handling capabilities to all pharmaceutically relevant classes

Frontage’s CMC Services group has received approval from the Drug Enforcement Agency (DEA) for the manufacture of Schedule I and II drug products, expanding its handling capabilities to all pharmaceutically relevant classes (Schedules I – V) regulated by the DEA. The approval also allows the company to conduct formulation development and GMP manufacturing projects for key medications used to treat pain and central nervous system (CNS) conditions.
The DEA manufacturing license requires maintenance of a secure facility with precise monitoring and electronic access controls, specialized operating procedures, staff requirements and physical security.
“Together with our existing capabilities, technology and experience, this approval is significant in helping establish Frontage’s product development services as a center of excellence for pain management therapies,” said Dr. Dongmei Wang, general manager, CMC Services. “Pain adversely affects more than a billion people worldwide, and the science of pain management delivery keeps improving. We are committed to pursuing enhancements for effective and efficient development, as pain management products command a larger portion of our clients’ CNS pipelines.”
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO